- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT05006404
Studie včasné proveditelnosti Autus Valve
Chlopeň Autus s nastavitelnou velikostí pro chirurgickou výměnu plicní chlopně Včasná studie proveditelnosti
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.
The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
California
-
Los Angeles, California, Spojené státy, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30322
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Ann and Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48109
- University of Michigan - Mott Children's Hospital
-
-
New York
-
New York, New York, Spojené státy, 10032
- Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27703
- Duke University
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Children's Hospital of Philadelphia
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84113
- University of Utah - Intermountain Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Spojené státy, 98105
- Seattle Children's Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.
-
Age 18 months to 16 years.
-
Male or female.
-
Subject has a native or repaired right ventricular outflow tract.
-
Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).
-
Subject has at least one of the following echocardiographic findings:
- Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
- Moderate or greater pulmonary regurgitation;
- Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
-
Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).
-
Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.
-
Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.
Exclusion Criteria:
Candidates will be excluded from the study if any of the following conditions are met:
- Subject requires valve replacement in a non-pulmonary position.
- Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
- Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
- Subject has pulmonary atresia and major aortopulmonary collaterals.
- Subject has significant peripheral pulmonary artery stenosis.
- Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
- Subject has active endocarditis or a history of infective endocarditis.
- Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
- Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
- Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
- Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
- Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
- Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
- Subject needs emergency cardiac or vascular surgery or intervention.
- Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
- Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
- Subject or parent/legal representative refuses blood transfusions.
- Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
- Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Autus Valve Arm
Pulmonary Valve Replacement Surgery with the Autus Valve |
Pulmonary valve replacement surgery with the Autus Valve |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Valve Implantation Primary Safety Endpoint
Časové okno: 30 Days post-valve implantation
|
Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:
|
30 Days post-valve implantation
|
|
Valve Implantation Primary Effectiveness Endpoint
Časové okno: 6 Months post-valve implantation
|
Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:
|
6 Months post-valve implantation
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Other Safety Outcome - Composite
Časové okno: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:
|
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Mortality
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Mortality, including: all cause, cardiac-related, procedure-related and device-related |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve Thrombosis
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Valve thrombosis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Thromboembolism
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Thromboembolism |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Cardiac or Valve Intervention
Časové okno: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Other cardiac or valve intervention (surgical or transcatheter) |
30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Major Hemorrhage
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Major hemorrhage |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Endocarditis
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Endocarditis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Hemolysis
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Hemolysis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Device Explantation
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Device explantation |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Adverse Events (AE)
Časové okno: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Adverse events |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve/Stent Fracture
Časové okno: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure. |
pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Časové okno: Immediately Post-Valve Implant Procedure
|
To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):
|
Immediately Post-Valve Implant Procedure
|
|
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Časové okno: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Časové okno: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Right Ventricular Measures
Časové okno: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Left Ventricular Measures
Časové okno: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Modified Ross Functional Classification
Časové okno: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Modified Ross Functional Class as assessed by the Site Investigators |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - PedsQL - Cardiac Module
Časové okno: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel. |
Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
|
Other Post-Implant Valve Expansion Safety Outcome - Composite
Časové okno: 30 days after each post-implant valve expansion procedure
|
Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:
|
30 days after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Časové okno: Immediately after each post-implant valve expansion procedure
|
To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:
|
Immediately after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Časové okno: 6 months after each post-implant valve expansion procedure
|
Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:
|
6 months after each post-implant valve expansion procedure
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- AUT-CP-001
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .